The syndromic multiplex diagnostics market has turned into an important part of the modern health care system because health care professionals are always trying to find new opportunities to make diagnoses of diseases much faster and more comprehensive. Unlike traditional methods of diagnosis, which involve many tests to be performed in order to get the result, syndromic multiplex diagnostics allows diagnosing multiple pathogens based on a single sample taken from a patient's body.
The Syndromic Multiplex Diagnostics Market was worth USD 3.28 billion in 2025 and forecasted to attain USD 6.63 billion by 2035 at a CAGR of 7.29% between 2026 and 2035, according to SNS Insider. The market size will be valued at USD 3.52 billion in 2026. The demand growth will be driven by the rising use of molecular diagnostics, increasing knowledge about the rapid detection of pathogens, and the continuous development of infectious disease monitoring. Multiplex systems cut down the time gap between sample collection and diagnostic through testing multiple bacteria, viruses, and parasites.
Gain Actionable Intelligence on Syndromic Multiplex Diagnostics Market – Request a Sample Report
Top 3 Syndromic Multiplex Diagnostics Companies
1. BioFire Diagnostics, LLC
BioFire Diagnostics is among the prominent firms in the syndromic multiplex diagnostics segment, producing panels that are aimed at identifying several pathogens from a single sample. The BIOFIRE FILMARRAY technology has become well-known for its syndromic rapid testing in respiratory, gastrointestinal and other infectious diseases. In February 2025, bioMerieux obtained approval from the FDA for the BIOFIRE FILMARRAY Gastrointestinal Panel Mid, which is a midplex molecular panel capable of diagnosing eleven agents that cause gastroenteritis in a single sample.
2. Becton, Dickinson and Company
Becton, Dickinson and Company (BD) plays a significant role in the market of syndromic multiplex diagnostics, due to its BD COR system that allows performing automated molecular tests and detecting gastrointestinal pathogens. The diagnostics solutions offered by BD allow labs to improve their workflow and to obtain useful data that will help manage the infectious disease. BD keeps developing its solutions for gastrointestinal molecular diagnostics. According to the 510(k) database of the U.S. Food and Drug Administration (FDA), there are BD Enteric Bacterial Panel and BD Enteric Bacterial Panel Plus that are used as gastrointestinal pathogen panel multiplex nucleic acid-based assays on the BD COR system.
3. DiaSorin S.p.A.
DiaSorin S.p.A. is working on reinforcing its position within the market of syndromic multiplex diagnostics due to its innovative LIAISON PLEX molecular diagnostics platform. This platform utilizes a customizable solution, where laboratories are able to choose clinically important targets instead of automatically testing each pathogen contained in the fixed panel, thus facilitating the process of diagnostic stewardship and reducing the cost of testing for laboratories. The LIAISON PLEX Gastrointestinal Flex Assay by DiaSorin is capable of testing up to 24 bacterial, viral, and parasitic targets from a single sample, providing laboratories the opportunity of customizing targets for testing. The development of additional LIAISON PLEX products, such as respiratory and blood culture panels, may allow DiaSorin to capitalize on the rising demand.
What is Driving the Future of the Syndromic Multiplex Diagnostics Market?
The increasing requirement of quick diagnosis is one of the biggest reasons behind the growth of the syndromic multiplex diagnostics market. Conventional diagnostics systems might involve separate tests for each test, which increases processing time and delays the decision about the treatment. This problem is solved by multiplex tests, wherein several pathogens responsible for a certain syndrome are tested at once. Such tests could be very beneficial in cases where symptoms produced by various pathogens coincide.
Moreover, the rising incidence of infectious conditions such as respiratory infections, gastrointestinal infections, and many others is providing another boost for market growth. The prompt detection allows doctors to pick proper therapies and avoid inappropriate antimicrobial therapy. In that way, multiplex testing helps promote antimicrobial stewardship through enhanced data provision.
The diagnostics laboratory dominated the end-user segment accounting for about 44.55% of the market share revenue in 2025 due to high volume of tests and availability of molecular diagnostics technology. The point of care clinic is set to witness the fastest CAGR of about 8.32%. The small and convenient multi-purpose platform will decrease the dependency on laboratory facilities and will help in making faster treatment decisions.
The Road Ahead
Future trends in the Syndromic Multiplex Diagnostics Market would include the development of broader pathogen panels, next generation sequencing, automation, and point-of-care testing. Laboratories are always looking for a technology which can offer them comprehensive coverage while having fast turnaround time and at the same time remaining efficient. Broader coverage up to 20 pathogens would enable laboratories to diagnose patients in complicated situations, while sequencing based diagnostic methods can add value in case if the unknown pathogen could not be detected with the help of conventional PCR panels.
The evolution of syndromic tests into decentralized healthcare facilities will present numerous opportunities up to 2035. Near patient care facilities such as point of care clinics and emergency rooms need efficient platforms that can provide clinical results rapidly. Moreover, the demand for accurate multiplex testing will increase further as the surveillance and antibiotic stewardship programs become more widespread. The companies that can provide extensive coverage of pathogens in combination with efficient testing and automation along with good clinical evidence can benefit from such evolution in the field of syndromic multiplexing.
